Cover Image
Market Research Report

Global Sepsis Diagnostics Market 2017-2021

Published by TechNavio (Infiniti Research Ltd.) Product code 570475
Published Content info 86 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Sepsis Diagnostics Market 2017-2021
Published: October 13, 2017 Content info: 86 Pages
Description

About Sepsis Diagnostics

Sepsis is a three-staged syndrome; it starts with systemic infections leading to severe sepsis and ultimately causing sepsis shock, which is regarded as a medical emergency. Population with weak immune system, which include children, older adults, and people with chronic diseases such as cancer, AIDS, diabetes, are prone to sepsis.

Sepsis occurs mainly due to bacterial, viral, and fungal infections. Gram-negative bacilli such as E. coli, P. aeruginosa, E. corrodens, and Haemophilus influenzae (which occurs mainly in neonates) are the main agents that cause infection, leading to sepsis. Other bacteria which causes sepsis are S. aureus, Streptococcus species, Enterococcus species, and Neisseria species.

Technavio's analysts forecast the global sepsis diagnostics market to grow at a CAGR of 6.74% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global sepsis diagnostics market for 2017-2021. To calculate the market size, the report considers the sales, volume and value of global sepsis diagnostics segment.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Sepsis Diagnostics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • bioMerieux
  • T2 Biosystems

Other Prominent Vendors

  • Alere
  • Abionic
  • AdvanDx
  • Aethlon Medical
  • AusDiagnostics
  • Beckman Coulter
  • Beckton Dickinson
  • Momentum Bioscience
  • Bio-Rad Laboratories
  • Bruker
  • Cepheid
  • Curetis
  • CytoSorbents
  • Fast Track Diagnostics
  • F. Hoffmann-La Roche
  • Fujirebio Europe
  • Hansa Medical
  • Hain Lifescience
  • Immunexpress
  • Inflammatix
  • Merck
  • miacom diagnostics
  • Mitsubishi Chemical Europe
  • Nanomix
  • QIAGEN
  • Radiometer
  • Response Biomedical
  • Sepset Biosciences
  • Siemens Healthineers
  • TCS Biosciences
  • Thermo Fisher Scientific

Market driver

  • Rising prevalence of hospital acquired infection (HAIs) globally
  • For a full, detailed list, view our report

Market challenge

  • High cost of sepsis treatment
  • For a full, detailed list, view our report

Market trend

  • Increasing use of biomarkers for sepsis
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR14892

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research methodology

PART 04: Introduction

  • Market outline

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by technology

  • Market overview
  • Immunoassay testing
  • POCT
  • Molecular testing

PART 07: Market segmentation by end-user

  • Market overview
  • Hospital and clinics
  • Diagnostic laboratories

PART 08: Geographical segmentation

  • Sepsis diagnostics market in Americas
  • Sepsis diagnostics market in EMEA
  • Sepsis diagnostics market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges

  • Market drivers
  • Market challenges

PART 11: Market trends

  • Development of novel products
  • Increasing use of biomarkers for sepsis
  • Increasing online campaigns for sepsis awareness

PART 12: Vendor landscape

  • Competitive landscape

PART 13: Key vendors

  • bioMerieux
  • T2 Biosystems
  • Key companies to watch
  • Other prominent vendors
  • List of abbreviations

PART 14: Appendix

List of Exhibits

  • Exhibit 01: Stages of sepsis
  • Exhibit 02: Products offered for severity of sepsis
  • Exhibit 03: Market overview: Global sepsis diagnostics market 2016-2021
  • Exhibit 04: Global sepsis diagnostics market 2016-2021 ($ millions)
  • Exhibit 05: Reimbursement for sepsis in the US
  • Exhibit 06: Five forces analysis
  • Exhibit 07: Market overview of sepsis diagnostics by technology 2016
  • Exhibit 08: Global sepsis diagnostics market by immunoassay testing 2016-2021 ($ millions)
  • Exhibit 09: Global sepsis diagnostics market by POCT 2016-2021 ($ millions)
  • Exhibit 10: Global sepsis diagnostics market by molecular testing 2016-2021 ($ millions)
  • Exhibit 11: Strategic analysis: Global sepsis diagnostics market by end-users 2016
  • Exhibit 12: Buying criteria for global sepsis diagnostics market by end user 2016
  • Exhibit 13: Global sepsis diagnostics market by geography in 2016 and 2021 ($ millions)
  • Exhibit 14: Market overview: Sepsis diagnostics market in Americas 2016-2021
  • Exhibit 15: Sepsis diagnostics market in Americas 2016-2021 ($ millions)
  • Exhibit 16: Market overview: Sepsis diagnostics market in EMEA 2016-2021
  • Exhibit 17: Sepsis diagnostics market in EMEA 2016-2021 ($ millions)
  • Exhibit 18: Market overview: Sepsis diagnostics market in APAC 2016-2021
  • Exhibit 19: Sepsis diagnostics market in APAC 2016-2021 ($ millions)
  • Exhibit 20: Market analysis: Sepsis-related to HAI
  • Exhibit 21: Ongoing clinical trials by NHS in the UK
  • Exhibit 22: Competitive structure analysis of global sepsis diagnostics market 2016
  • Exhibit 23: Market penetration of various global sepsis diagnostics market providers 2016
  • Exhibit 24: Strategic success factors of companies in global sepsis diagnostics market 2016
  • Exhibit 25: bioMerieux: Key highlights
  • Exhibit 26: bioMerieux: Strength assessment
  • Exhibit 27: bioMerieux: Strategy assessment
  • Exhibit 28: bioMerieux: Opportunity assessment
  • Exhibit 29: T2 Biosystems: Key highlights
  • Exhibit 30: T2 Biosystems: Strength assessment
  • Exhibit 31: T2 Biosystems: Strategy assessment
  • Exhibit 32: T2 Biosystems: Opportunity assessment
  • Exhibit 33: Abbott: Company assessment
  • Exhibit 34: Nanosphere: Company assessment
Back to Top